Amorcyte - Cell Therapy Solutions for Cardiovascular Disease

About Amorcyte

Leadership

Investors

Technology

Clinical Trials

Corporate Development

News & Events

Amorcyte, a NeoStem company, develops cell therapy products to treat cardiovascular disease.

Its lead product candidate, AMR-001, for the prevention of major adverse cardiac events following acute myocardial infarction (AMI), has completed Phase I clinical trials demonstrating feasibility, safety and biologic activity at a threshold dose. This is the first prospective stem cell trial in AMI ever conducted that has established a statistically significant relationship between dose and effect. Amorcyte is now poised to begin the PreSERVE AMI Phase II trial in the first quarter of 2012. The trial has been designed to evaluate the potential of AMR-001 to improve perfusion, preserve cardiac function and improve clinical outcomes.

Amorcyte will be provided with a pharmaceutical grade cGMP manufactured product thact can be distribted commercially by Progenitor Cell Therapy, another NeoStem company and a leading provider of clinical, manufacturing and other services for the cell therapy industry.

Click here, to download a fact sheet on Amorcyte and AMR-001.

NEOSTEM ACQUIRES AMORCYTE, A CLINICAL STAGE CARDIOVASCULAR DISEASE CELL THERAPY COMPANY

New York, NY, October 17, 2011)

NEOSTEM PROVIDES UPDATE ON AMORCYTE CLINICAL PROGRESS AND REPORTS RESULTS FOR SECOND QUARTER

New York, NY, August 15, 2011

NEOSTEM SIGNS DEFINITIVE MERGER AGREEMENT TO ACQUIRE AMORCYTE IN EQUITY TRANSACTION

New York, NY, July 14, 2011

AMORCYTE STEM CELL THERAPY DEMONSTRATES CLINICALLY SIGNIFICANT REPERFUSION IN SEVERE HEART ATTACK PATIENTS

American Heart Journal Publication Establishes Achievement of Threshold Dose

Allendale, NJ, December 21, 2010

AMORCYTE REPORTS PHASE I RESULTS OF AMR-001 TO IMPROVE RECOVERY FROM SEVERE HEART ATTACK AT ACC ANNUAL SCIENTIFIC SESSION

First Stem Cell Trial to Show Dose-related Significant Improvement in Perfusion

Orlando, Fla, March 30, 2009

After Heart Attack, Bone Marrow Stem Cells Increase Blood Flow Within Heart

Orlando, Fla, March 30, 2009